Idexx Laboratories Inc IDXX
We take great care to ensure that the data presented and summarized in this overview for IDEXX LABORATORIES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IDXX
View all-
Vanguard Group Inc Valley Forge, PA9.7MShares$4.34 Billion0.09% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$4.3 Billion0.11% of portfolio
-
State Street Corp Boston, MA3.63MShares$1.62 Billion0.08% of portfolio
-
Alliancebernstein L.P. New York, NY3.14MShares$1.41 Billion0.55% of portfolio
-
Terry Smith Fundsmith LLP | London, X02.66MShares$1.19 Billion5.41% of portfolio
-
Geode Capital Management, LLC Boston, MA2.22MShares$994 Million0.1% of portfolio
-
Bamco Inc New York, NY2.04MShares$911 Million2.89% of portfolio
-
Franklin Resources Inc San Mateo, CA1.38MShares$617 Million0.21% of portfolio
-
Invesco Ltd. Atlanta, GA1.32MShares$593 Million0.14% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.27MShares$569 Million0.07% of portfolio
Latest Institutional Activity in IDXX
Top Purchases
Top Sells
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Insider Transactions at IDXX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 06
2024
|
Jonathan W Ayers Director |
BUY
Bona fide gift
|
Indirect |
532,179
+48.94%
|
-
|
Sep 06
2024
|
Jonathan W Ayers Director |
SELL
Bona fide gift
|
Indirect |
302,179
-100.0%
|
-
|
Sep 06
2024
|
Jonathan W Ayers Director |
SELL
Bona fide gift
|
Direct |
230,000
-86.58%
|
-
|
Sep 06
2024
|
M Anne Szostak Director |
SELL
Open market or private sale
|
Indirect |
500
-100.0%
|
$234,500
$469.37 P/Share
|
Sep 05
2024
|
M Anne Szostak Director |
BUY
Bona fide gift
|
Indirect |
500
+50.0%
|
-
|
Sep 05
2024
|
M Anne Szostak Director |
SELL
Bona fide gift
|
Indirect |
500
-7.62%
|
-
|
Sep 01
2024
|
Michael Schreck Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
48
-4.99%
|
$23,088
$481.33 P/Share
|
Sep 01
2024
|
Michael Schreck Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
164
+14.58%
|
-
|
Sep 01
2024
|
Martin Alexander Smith Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
5
-0.97%
|
$2,405
$481.33 P/Share
|
Sep 01
2024
|
Martin Alexander Smith Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
18
+3.38%
|
-
|
Aug 05
2024
|
Jonathan Jay Mazelsky President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
170
-0.21%
|
$77,350
$455.08 P/Share
|
Aug 05
2024
|
Jonathan Jay Mazelsky President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
384
+0.47%
|
-
|
Aug 05
2024
|
Brian P Mckeon EVP, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-0.38%
|
$53,235
$455.08 P/Share
|
Aug 05
2024
|
Brian P Mckeon EVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
192
+0.61%
|
-
|
May 17
2024
|
Bruce L. Claflin Director |
SELL
Open market or private sale
|
Direct |
200
-55.4%
|
$108,000
$540.8 P/Share
|
May 08
2024
|
M Anne Szostak Director |
BUY
Bona fide gift
|
Indirect |
257
+3.77%
|
-
|
May 08
2024
|
M Anne Szostak Director |
SELL
Bona fide gift
|
Direct |
257
-100.0%
|
-
|
May 06
2024
|
Jonathan W Ayers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
257
+0.1%
|
-
|
May 06
2024
|
Irene Chang Britt Director |
BUY
Exercise of conversion of derivative security
|
Direct |
208
+50.0%
|
-
|
May 06
2024
|
Asha Collins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
257
+24.81%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 95.6K shares |
---|---|
Grant, award, or other acquisition | 1.43K shares |
Bona fide gift | 533K shares |
Payment of exercise price or tax liability | 5.05K shares |
---|---|
Open market or private sale | 72.5K shares |
Bona fide gift | 550K shares |